Bone sialoprotein promoter-driven Herpes simplex virus thymidine kinase (BSP-HSV-TK)

Bone sialoprotein (BSP) promoter-driven Herpes simplex virus thymidine kinase (HSV-TK) is a specialized gene therapy construct designed for the targeted treatment of BSP-positive malignancies, particularly those with a high affinity for bone metastasis. Bone Sialoprotein is a non-collagenous matrix protein typically restricted to mineralized tissues, but its promoter is frequently hijacked and overexpressed by breast, prostate, and lung cancer cells during the process of osteomimicry. By placing the HSV-TK 'suicide gene' under the control of the BSP promoter, the therapeutic effect is transcriptionally targeted to tumor cells while sparing most healthy non-skeletal tissues. When the prodrug ganciclovir is administered systemically, the localized expression of HSV-TK within the tumor converts the drug into a potent cytotoxin that halts DNA replication. This approach not only kills the primary transfected cells but also induces a 'bystander effect,' where the toxic metabolites spread to neighboring cancer cells through gap junctions. Consequently, this system serves as a precision tool to combat the progression of bone-metastatic disease by exploiting the unique gene expression profile of aggressive cancer cells.

Other names

IBSP promoter-HSV-TKBSP-TK/GCV systemBone sialoprotein-targeted suicide gene therapyBSP-driven thymidine kinase

The BSP promoter restricts the expression of the Herpes simplex virus thymidine kinase (HSV-TK) enzyme specifically to cancer cells that overexpress Bone Sialoprotein (BSP). Once expressed, the HSV-TK enzyme phosphorylates the prodrug ganciclovir (GCV) into ganciclovir monophosphate, which is subsequently converted by cellular kinases into ganciclovir triphosphate. This metabolite acts as a deoxyguanosine triphosphate analog that is incorporated into nascent DNA strands, causing chain termination, inhibition of DNA polymerase, and subsequent cell death via apoptosis.